FDA Sets Peptide Impurity Thresholds as Low as 0.10%, Oath Research Analysis Finds

The U.S. FDA guidance highlighted for synthetic peptide drugs requires firms to identify impurities above 0.10% and cap any new impurities at 0.5%. The article is framed as an Oath Research analysis of these regulatory thresholds, with no reported company financial impact or market-wide implications.

Analysis

The U.S. FDA guidance highlighted for synthetic peptide drugs requires firms to identify impurities above 0.10% and cap any new impurities at 0.5%. The article is framed as an Oath Research analysis of these regulatory thresholds, with no reported company financial impact or market-wide implications.